ASCO 2021 | CheckMate 920: nivo plus ipi for advanced RCC with brain metastases

Hamid Emamekhoo, MD, The University of Wisconsin School of Medicine and Public Health, Madison, WI, shares the latest safety and efficacy data for combined nivolumab (nivo) plus ipilimumab (ipi) treatment in patients with previously untreated advanced renal cell carcinoma (RCC) and brain metastases in the CheckMate 920 study (NCT02982954). CheckMate 920 is an ongoing Phase IIIb/IV multi-cohort trial of nivo plus ipi treatment in patients with advanced RCC with a high unmet medical need. A total of 28 patients with brain metastases were treated in the study and followed for a minimum of 24.5 months. The regimen showed no new safety signals and no grade 5 immune-mediated adverse events occurred. An overall response rate of 32% was achieved, adding to previous findings of encouraging activity in patients with brain metastases. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.